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Q fever is zooantroponozis with global distribution caused by the strictly intracellular bacterium Coxiella 
burnetii. Causative agent of Q fever is an obligate intracellular parasite, classified in the genus Coxiella, family 
Coxiellaceae, class Gammaproteobacteria. The importance of the disease was assessed both in terms of human 
health and the serious economic damage they cause on livestock. Clinical manifestation of Q fever in humans is 
characterized by a wide variety - from asymptomatic infection to a chronic disease that can be fatal. Several 
basic methods have been developed to detection of C. burnetii. PCR and C. burnetii genomic sequences in 
whole blood are a sensitive and safe method of detection, with >90% sensitivity. A four-fold or greater rise of 
(CF) antibody (phase 2) between the paired sera is also diagnostic approach. Sensitivity of a four-fold rise in 
titre has been estimated as 73% ÷78% and specificity has been estimated as 90%, respectively. EIA is method 
with highly sensitive and specific. EIA detect IgM and then IgG antibodies which develop to phase II antigens 
in 10 to 14 days from symptom onset. IFA tests are of particular value for confirmation of acute infection and 
for diagnosis of chronic infection with high sensitivity. The technique detected IgG, IgM and IgA 
immunoglobulin classes. Suitable specimens for C.  
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burnetii detection are blood samples. Although scientific interest in Q fever has always existed, a number of 
facts concerning the unforeseen nature of the epidemic, various clinical manifestations both in humans and in 
animals, the opportunities for chronic and other features of infection remain unclear. For this reason, timely and 
highly sensitive laboratory diagnosis is crucial for the outcome of the disease and subsequent treatment and 
monitoring. 
Keywords: Coxiella burnetii; Q fever; PCR; EIA IgM/IgG; IFA. 
1. Introduction 
Zooantroponozes are constantly growing group of infections including diseases manifesting in the form of 
epizootic outbreaks and epidemics, with serious human health, environmental, economic and socio-domestic 
consequences. Rapidly advancing climate changes brought about by global warming, more intense trade in live 
animals and globalizing world intensified existing natural and antropurgic outbreaks of several diseases with 
zoonotic potential and created conditions for expanding the area of the spread of other infections having status 
for exotic infections in countries in the temperate zone of the planet. These diseases are among the priority areas 
of the World Health Organization (WHO), the European Center for Disease Prevention and Disease Control 
(ECDC) and the European Agency for Food Safety (EFSA). 
2.  Epidemiology and molecular genetic  
Q fever is zooantroponozis with global distribution caused by the strictly intracellular bacterium Coxiella 
burnetii, established on all continents, with the exception of New Zealand [1]. The host range susceptible to 
infection types is too wide and includes a large number of wild and domesticated mammals and many birds and 
amphibians, and the ability of ticks stored and transmitted as vectors infectious agent associated with the 
formation and maintenance for an extended period during natural outbreaks [2; 3; 4]. Coxiella burnetii is 
included in category "B" list of potential biological weapons [5]. Causative agent of Q fever is an obligate 
intracellular parasite, classified in the genus Coxiella, family Coxiellaceae, class Gammaproteobacteria. There is 
a phase variation in the development of C. burnetii which allows the serological differentiation between an acute 
and a chronic form. The main structural elements of C. burnetii are: cytoplasm, nucleic and surface structures 
[6]. Its genome contains one molecule of DNA with sizes from 1.5 to 2.4 x 106 base pairs, the length of which 
varies in different strains as well as one of the five types of plasmids (QpHI, QpRS, QpDG, QpDV and one 
anonymous) (30-51 kbp), which constitute about 2% of the total genetic information [7]. For the rapid detection 
and identification of C. burnetii have been developed and widely used a complex of methods: serological 
(immunofluorescence, CFT, ΕLISA etc.), cell culture, and molecular biological (conventional, nested, real-time 
PCR, etc.) [8]. The introduction of PCR significantly increased the sensitivity and specificity of early etiological 
diagnosis and sequencing of genomic regions from different strains of C. burnetii, permit their differentiation 
and characterization with regard to such important biological properties, responsible for the virulence of the 
agent as adhesion, penetration, intracellular transport, "escape" from the immune response, pathogenesis and 
others [9; 10]. There are 2134 identified gene sequences of the genome of C. burnetii so far, 719 (33.7%) of 
them are unique [7]. In the global gene bank there are more than 30 genotypes C. burnetii, allocated on the basis 
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of phylogenetic analysis at 6 genogroups (Ι - VI), some of which occur everywhere in endemic and non-endemic 
areas [11; 12]. Different genotypes vary by pathogenic properties, clinical outcome and noso-geographical 
spread, but the data are conflicting [13]. Regardless of the early reports of applicability of various methods 
(MLVA, MST, RFLP, etc.) for genetic identification and detection of specific gene determinants of C. burnetii, 
encoding the factors of virulence/pathogenicity, resistance to antibiotics, etc. [14; 15], their information is 
incomplete and does not provide a definite answer. The importance of the disease was assessed both in terms of 
human health and the serious economic damage they cause on livestock. For the first time the disease was 
described in humans by E. Derrick in 1935, which gave the name "Q fever" (from eng. "query" - "unclear") [16], 
followed by numerous other reports. The infection is endemic in almost all countries in Europe, where they are 
registered epidemic outbreaks with different sizes, as well as varying the degree of infestation of farm animals 
[13; 17]. 
3.  Pathogenesis, transmission and tropism  
Clinical manifestation of Q fever in humans is characterized by a wide variety - from asymptomatic infection to 
a chronic disease that can be fatal. In 40% of clinically manifested cases of acute Q-infection was observed self-
limiting febrile illness [18] and/or primary atypical pneumonia [4], it is possible in some cases to develop 
granulomatous hepatitis as well [19]. Of particular note is the persistent form of C. burnetii infection, which is 
severe, with high lethality [20]. Q rickettsial endocarditis is the most common form of chronic infection, patients 
with valvular and vascular lesions are at high-risk [21]. Many people infected with Q fever never show 
symptoms. If you do have symptoms, you'll probably notice them between three and 30 days after exposure to 
the bacteria. Signs and symptoms may include: 
 High fever, up to 105 F (410C) 







 Sensitivity to light 
In animals, the disease usually is subclinical. In ruminants, however, infection can occur with miscarriages, birth 
of non-viable offspring and reproductive problems, leading in some cases to serious economic losses. Some data 
suggest that Coxielloses in animal, possibly in association with other factors of an infectious nature may 
manifest with other clinical characteristics (pneumonia, mastitis), but validation of any opinion requires further 
research, including experimental. Excretion of the agent can last more than four months. This fact is crucial, 
since the infected animals are the main source of infection inpeople. The main role in this play productive 
ruminants (cows, sheep and goats) that emithuge amount of C. burnetii in amniotic fluid and placentas at normal 
birth or in cases of abortion. Although to a lesser extent, the causative agent is excreted in milk, urine and 
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faeces. Other domestic animals and birds have less participation in epidemiological process. The mechanism of 
transmission of C. burnetii in humans is realized mainly by inhalation of aerosol particulates, contaminated with 
the pathogen [22] and, more rarely alimentary. The bite of infected ticks has its epidemiological significance to 
natural outbreaks. 
4.  Laboratory Diagnosis 
Several basic methods have been developed to detection of C. burnetii [23-26] (Fig 1). 
4.1 Direct detection of C. burnetii 
Stains and direct immunofluorescence for light microscopy and electron microscopy are not performed 
routinely. C. burnetii are highly infectious and unfixed tissue samples for examination for C. burnetii should be 
handled in a biohazard cabinet until fixed with formalin, dehydrated methanol or acetone. C. burnetii cultures 
are risk level 3 organisms and should only be handled by immune staff in a PC3 facility [28].  
4.2 Polymerase chain amplification (PCR) 
PCR of C. burnetii genomic sequences in whole blood a sensitive and safe method of detection [27]. The initial 
extraction of the DNA involves procedures – proteinase K treatment, chloroform phenol extraction, heating over 
90
0
C – which inactivate viable C. burnetii. Test Sensitivity and Specificity - This method has >90% sensitivity 
compared with serodiagnosis early in infection. It is highly specific. Sensitivity decreases with progression of 
the illness with no detection after day 17. However, sensitivity in chronic Q fever is only 50-60%. Suitable 
Specimens -Tissue, whole blood, serum. Suitable Test acceptance/validation criteria - In run and positive and 
negative control (non-template controls), extraction control. 
4.3  Serological diagnosis 
Historically, the most frequently used technique was complement fixation with C. burnetii Phase 2 antigen, and 
later, in addition, with Phase 1 antigen. Phase 2 antibody is the first to be detected and phase 1 antibody is 
invariably present in chronic Q fever infection, including endocarditis, with or without phase 2 antibody. 
Examination of acute and convalescent sera fulfils the most reliable criteria for an acute infection: a four-fold or 
greater rise of (CF) antibody (phase 2) between the paired sera is diagnostic. The technique has the limitations 
that it is labour intensive and does not measure IgM so that a positive result may not be obtained until late in the 
disease. Also, it does not measure IgA antibody which may be important in Q fever endocarditis [29; 30]. Test 
Sensitivity and specificity - CFT measures mainly IgG so may not be positive early in acute Q fever when the 
patient first presents and only IgM antibody may be present. The test should be repeated in 2-4 weeks and run in 
parallel with the first sample to determine titre changes. Sensitivity of a four-fold rise in titre has been estimated 
as 73% ÷78% and specificity has been estimated as 90%, respectively. Suitable specimens - Blood samples. 
Ideally acute and convalescent samples should be provided, especially in acute Q fever, to monitor titre changes. 
Suitable test acceptance/validation criteria - Use of internal and external controls and test performance should 
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comply with method. 
4.4 Enzyme immunoassay (EIA) Testing 
Commercial kits are available to measure IgM and IgG antibodies to phase 2 antigens. If only a single 
convalescent serum is available it may be difficult to distinguish persistent IgM from a past infection from that 
of a current infection, as not all Q fever cases make the IgM to IgG switch. IgM has been observed to persist for 
over 600 days after an acute Q fever infection. While acute primary Q fever is confirmed with reasonable 
efficiency with the EIA test it is unwise to rely solely on this method if chronic Q fever infection is suspected 
and where interpretation has to be based on the height of titers to Phase 1 and 2 antigens in the IgG and IgA 
classes. These tests are not quantitative so should be used only as a screening test to select samples for the more 
labour intensive CFT or IFA testing. IgM and then IgG antibodies develop to phase II antigens in 10 to 14 days 
from symptom onset. Seroconversion or a fourfold rise in phase II IgG or CFT titre in convalescent serum is 
diagnostic of Q fever. Suitable specimens – Blood samples. Ideally acute and convalescent samples should be 
collected and tested in parallel. Test sensitivity and specificity - Published data suggest that EIA is highly 
sensitive and specific. Data regarding commercial assays should be sought from the manufacturer. Suitable test 
acceptance/validation criteria - Follow manufacturer’s instructions. 
4.5 IFA testing 
IFA tests are of particular value for confirmation of acute infection and for diagnosis of chronic infection. The 
technique involves titrating sera by immunofluorescence (IFA) on microdots of C. burnetii expressing phase 1 
or phase 2 antigens with conjugates directed against IgG, IgM and IgA immunoglobulin classes [31]. Suitable 
Specimens - Blood samples. Sequential samples should be tested in parallel. Test Sensitivity and Specificity - 
The microdot phase 1 and 2 IgM, and IgG and the IgA tests are highly sensitive and specific for the detection of 
Q fever antibodies. 
 
Figure 1: Typical serological and molecular response in acute and chronic Q fever 
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5.  Conclusion 
Although scientific interest in Q fever has always existed, a number of facts concerning the unforeseen nature of 
the epidemic, various clinical manifestations both in humans and in animals, the opportunities for chronic and 
other features of infection remain unclear. Q fever prevalence is unknown and it is likely that the number of 
cases of  is underestimated. At the same time changes in migration processes, the threat of bioterrorism, the 
problems in national and global scale associated with environmental and other factors increased the risk of 
spreading morbidity in emerging noso-geographical areas. Therefore, the diagnosis must be considered in the 
case of an unexplained fever, especially if the fever recurred following contact with possibly contaminated 
mammals. The best tests for diagnosis are those which permit the direct detection of bacteria. They include shell 
vial cell culture, PCR amplification, and immunodetection with tissue biopsy specimens. All these techniques 
require a level 3 biosafety laboratory and trained personnel due to the extreme infectivity of C. burnetii. In 
chronic cases, the techniques that allow the direct detection of C. burnetii in blood or tissues should be used 
before the beginning of therapy. As for indirect specific diagnosis, the technique to be used should be very 
sensitive and should detect antibodies early in the course of the disease. Although many techniques have been 
described, immunofluorescence assay is the reference method. It is both very specific and sensitive. The 
presence of cross-reacting antibodies should be investigated by cross-adsorption followed by Immunoblot 
testing [32]. We recommend that all patients with possible C. burnetii infection to be tested by combination of 
serological and molecular assayes  and be monitored for their immune status and persistent infection. 
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